Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Rishabh K, Simhal"'
Autor:
Kerith R. Wang, Rishabh K. Simhal, Cassra B. Clark, Mark J. Mann, James R. Mark, Costas D. Lallas, Robert Den, Edouard J. Trabulsi
Publikováno v:
Advances in Urology, Vol 2024 (2024)
Objective. To examine one academic institution’s experiences with SpaceOAR placement, its associated complications, and periprocedural characteristics that affect outcomes for the purpose of quality improvement. Materials and Methods. We conducted
Externí odkaz:
https://doaj.org/article/7096467d775d495a968fa00435f3b442
Autor:
Rishabh K. Simhal, Tamir N. Sholklapper, Anish K. Simhal, Alan L. Zwart, Malika T. Danner, Deepak Kumar, Nima Aghdam, Simeng Suy, Ryan A. Hankins, Keith J. Kowalczyk, Sean P. Collins
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionStereotactic Body Radiation Therapy (SBRT) has emerged as a definitive therapy for localized prostate cancer (PCa). However, more data is needed to predict patient prognosis to help guide which patients will benefit most from treatment. T
Externí odkaz:
https://doaj.org/article/28ebc48acdbd4509862d70d28e309b7a
Autor:
Rishabh K. Simhal, Yash B. Shah, Kerith R. Wang, Jonathan Martin, Sohan Shah, Adam Wright, Maria D’Amico, Joon Yau Leong, Costas D. Lallas, Patrick J. Shenot, Mihir S. Shah, Alana M. Murphy
Publikováno v:
Urology.
Autor:
Kerith R. Wang, Yash B. Shah, Rishabh K. Simhal, Andrea Quinn, Andrew Denisenko, Erica Mann, Jessica Clark, Jared Raikin, Costas D. Lallas
Publikováno v:
Urology.
Autor:
Yash B. Shah, Rishabh K. Simhal, Kerith R. Wang, Hanan Goldberg, Costas D. Lallas, Thenappan Chandrasekar
Publikováno v:
Journal of clinical medicine, vol 12, iss 1
Journal of Clinical Medicine; Volume 12; Issue 1; Pages: 175
Journal of Clinical Medicine; Volume 12; Issue 1; Pages: 175
There remains debate surrounding partial (PN) versus radical nephrectomy (RN) for T1b-T2 renal cell carcinoma (RCC). PN offers nephron-sparing benefits but involves increased perioperative complications. RN putatively maximizes oncologic benefit with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91f40ff1ff12ad818552a879a0391650
https://escholarship.org/uc/item/5fs6h79j
https://escholarship.org/uc/item/5fs6h79j
Autor:
Yash B. Shah, Connor McPartland, Kerith R. Wang, Rishabh K. Simhal, Alana Murphy, Patrick Shenot, Leonard Gomella, Costas D. Lallas
Publikováno v:
Urology.
Autor:
Xiangyu Liu, Ali Masoudi, Alem W. Kahsai, Li-Yin Huang, Biswaranjan Pani, Dean P. Staus, Paul J. Shim, Kunio Hirata, Rishabh K. Simhal, Allison M. Schwalb, Paula K. Rambarat, Seungkirl Ahn, Robert J. Lefkowitz, Brian Kobilka
Publikováno v:
Science. 364:1283-1287
Positive reinforcement in a GPCR Many drug discovery efforts focus on G protein–coupled receptors (GPCRs), a class of receptors that regulate many physiological processes. An exemplar is the β 2 -adrenergic receptor (β 2 AR), which is targeted by
Publikováno v:
Sports medicine and arthroscopy review. 29(2)
Posterior cruciate ligament (PCL) injuries can be debilitating knee injuries, having involvement in up to 44% of traumatic knee injuries. However, isolated PCL injuries are relatively infrequent. Therefore, effective evidence-based rehabilitation pro
Autor:
Laura M. Wingler, Biswaranjan Pani, Dean P. Staus, Paula K. Rambarat, Paul J. Shim, Robert J. Lefkowitz, Jin Lei, Thomas Franch, Mikkel Vestergaard, Lillian D. Sun, Eva Kampmann Olsen, Thomas T. Xu, Li-Yin Huang, Shuai Zhao, Seungkirl Ahn, Gitte Nystrup Husemoen, Alem W. Kahsai, Rishabh K. Simhal, Xin Chen
Publikováno v:
Molecular Pharmacology
Conventional drug discovery efforts at the β2-adrenoceptor (β2AR) have led to the development of ligands that bind almost exclusively to the receptor’s hormone-binding orthosteric site. However, targeting the largely unexplored and evolutionarily
Autor:
Xiangyu, Liu, Ali, Masoudi, Alem W, Kahsai, Li-Yin, Huang, Biswaranjan, Pani, Dean P, Staus, Paul J, Shim, Kunio, Hirata, Rishabh K, Simhal, Allison M, Schwalb, Paula K, Rambarat, Seungkirl, Ahn, Robert J, Lefkowitz, Brian, Kobilka
Publikováno v:
Science (New York, N.Y.). 364(6447)
Drugs targeting the orthosteric, primary binding site of G-protein coupled receptors are the most common therapeutics. Allosteric binding sites, elsewhere on the receptors, are less well-defined, and so less exploited clinically. We report the crysta